GlassScriptPhysician profile
Lynn Zhang
NPI 1669767554
$3,739.53
in general payments reported to CMS, 2019-2025
35 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,958 · 2020: $566 · 2021: $728 · 2022: $290 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $386.22 | 2019-2021 | |
| Biogen, INC. | $349.77 | 2019-2022 | |
| Lilly USA, LLC | $344.55 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $262.80 | 2020-2021 | |
| Ucb, INC. | $244.56 | 2019-2021 | |
| Allergan, INC. | $244.55 | 2019-2022 | |
| Emd Serono, INC. | $196.77 | 2019-2021 | |
| Lundbeck LLC | $191.18 | 2021 | |
| Genentech USA, INC. | $152.64 | 2019-2020 | |
| Genzyme Corporation | $144.22 | 2019-2020 | |
| Medtronic USA, INC. | $125.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $123.30 | 2025 | Datroway |
| Teva Pharmaceuticals USA, INC. | $97.74 | 2019-2022 | |
| Sk Life Science, INC. | $75.09 | 2020-2022 | |
| Harrow Eye, LLC | $74.13 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $71.52 | 2019 | |
| Amgen INC. | $70.71 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $69.54 | 2019 | |
| Mdd US Operations, LLC | $57.41 | 2019 | |
| Eisai INC. | $52.16 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $45.17 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.49 | 2022 | |
| Abbvie INC. | $38.01 | 2021-2022 | |
| Acorda Therapeutics, INC | $35.96 | 2019 | |
| Sunovion Pharmaceuticals INC. | $34.97 | 2019 | |
| Ge Healthcare | $32.85 | 2019 | |
| Jazz Pharmaceuticals INC. | $29.04 | 2022 | |
| Neurocrine Biosciences, INC. | $27.08 | 2019-2021 | |
| Avion Pharmaceuticals | $22.59 | 2022 | |
| Adamas Pharmaceuticals, INC. | $20.45 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.65 | 2020 | |
| Greenwich Biosciences, INC. | $17.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.94 | 2021 | |
| Aquestive Therapeutics, INC. | $13.67 | 2019 | |
| Livanova USA, INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.